Effectiveness and safety of vonoprazan‐based regimen for Helicobacter pylori eradication: A meta‐analysis of randomized clinical trials

作者：Yang Chen, Sai Li, Taoyang Huang, Hongju Lin, Zhihui Jiang, Yongyang He, Junjie Yuan, Huijie An · 发表于：Journal of Clinical Pharmacy and Therapeutics · 年份：2022 · DOI：10.1111/jcpt.13637 · 被引用次数：29 · 研究领域：Helicobacter pylori-related gastroenterology studies、Gastroesophageal reflux and treatments、Gastrointestinal motility and disorders

WHAT IS KNOWN AND OBJECTIVE: The Helicobacter pylori (H. pylori) eradication rate of proton pump inhibitor (PPI)-based regimen remains decreasing. Vonoprazan (VPZ), a stronger and longer-lasting acid blocker, has been proposed to treatment of H. pylori infection. However, previous reviews did not have a pre-established study protocol and did not conduct a comprehensive search of the database, so the results obtained were not robust. We aimed to perform a meta-analysis to assess the effectiveness and safety of VPZ-based regimens for treatment of H. pylori infection in comparison with other regimens. METHODS: We conducted a systematic literature search on PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials and ChiCTR Register. Randomized clinical trials comparing VPZ-based regimens with similar eradication regimens without VPZ in the treatment of H. pylori infection were included. Eradication rate, compliance of the patients and side effects were specified as the primary outcomes. RevMan 5.4 software was used to analyze the RCTs and provide pooled risk ratio (RR) with 95% confidence intervals (CI). Systematic searches, study selection, data extraction, risk of bias assessment and statistical analysis were performed by two independent researchers according to the predesigned criteria on the PROSPERO. RESULTS AND DISCUSSION: A total of 8 RCTs with 2012 patients qualified for evaluation. The results showed that the eradication rate of VPZ-containing regimens was signi...